John Ballantyne, Angel Investor

John Ballantyne is an angel investor who has made at least 10 investments. His latest investment was in the Seed Round of VerImmune in September 2024. Verlmmune is an immuno-oncology company that is developing a first-class cancer therapy known as anti-tumor immune redirection. His portfolio also includes GlucoTrack, Elegen, Thrixen, Cytonus Therapeutics, JURA Bio, CureLab Oncology, Myosana Therapeutics, CureLab Veterinary, and Kytopen. John is a former CSO and VP of Aldervon, a biotechnology research company that is now part of Danaher.